Jennison Associates
NKTR icon

Jennison Associates’s Nektar Therapeutics NKTR Stock Holding History

Jennison Associates’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-829
Closed -$758K – 689
2018
Q3 		$758K Buy
+829
New +$708K ﹤0.01% 577
2018
Q2 		– Sell
-25,665
Closed -$40.9M – 692
2018
Q1 		$40.9M Buy
25,665
+8,771
+52% +$11.3M 0.04% 282
2017
Q4 		$15.1M Buy
+16,894
New +$9.99M 0.01% 435

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jennison Associates's NKTR Position: Q4 2018 in Review

Jennison Associates sold out of Nektar Therapeutics (NKTR) in Q4 2018, closing a stake of 829 shares — an estimated $758K sold.

Jennison Associates first reported a position in NKTR in Q4 2017 and held it in 3 quarters. The position peaked at $40.9M in Q1 2018. 343 funds tracked by Wall St. Rank hold NKTR as of Q4 2018.

  • Jennison Associates reported no remaining Nektar Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Jennison Associates sold 829 Nektar Therapeutics shares in Q4 2018, an estimated $758K.
  • Jennison Associates first reported a position in Nektar Therapeutics in Q4 2017 and held it in 3 quarters.
  • Jennison Associates's Nektar Therapeutics position peaked at $40.9M in Q1 2018.
  • 343 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2018.

Based on Jennison Associates's 13F filing for Q4 2018, filed 6 Feb 2019.